Literature DB >> 10430760

Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry.

M Haim1, M Benderly, D Brunner, S Behar, E Graff, H Reicher-Reiss, U Goldbourt.   

Abstract

BACKGROUND: The association between elevated blood triglyceride levels and subsequent mortality risk in patients with established coronary heart disease (CHD) has been investigated rarely. The aim of the present study was to investigate this association. METHODS AND
RESULTS: We evaluated mortality over a mean follow-up time of 5. 1 years among 9033 male and 2499 female CHD patients who were screened for participation in the Bezafibrate Infarction Prevention (BIP) Study. A stepwise increase in mortality with increasing serum triglyceride levels was observed in patients with desirable or elevated serum total cholesterol levels and in patients with either desirable or abnormally low HDL cholesterol levels. Multivariate adjustment for factors other than HDL cholesterol yielded a slightly increased adjusted mortality risk with a 1-natural-log-unit elevation of triglyceride levels in men (hazard ratio [HR] 1.14, 95% CI 1.00 to 1.30) and women (HR 1.37, 95% CI 1.04 to 1.88). Excess covariate-adjusted risk was noted among patients with elevated total and LDL cholesterol and in women with HDL cholesterol levels >45 mg/dL. After additional adjustment for HDL cholesterol, the risk of mortality with a 1-natural-log-unit elevation of triglycerides declined in men (HR 1.09, 95% CI 0.94 to 1.26) and in women (HR 1.10, 95% CI 0.80 to 1.50). A trend for increased mortality risk remained in patients with elevated total and LDL cholesterol and in women with HDL cholesterol >45 mg/dL.
CONCLUSIONS: Elevated triglyceride levels were associated with a small, independent increased mortality risk in CHD patients. This risk may be increased among subgroups of patients with elevated total cholesterol and LDL cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430760     DOI: 10.1161/01.cir.100.5.475

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

1.  Marked Differences of Haplotype Tagging SNP Distribution, Linkage, and Haplotype Profile of APOA5 Gene in Roma Population Samples.

Authors:  Katalin Sumegi; Balazs Duga; Bela I Melegh; Zsolt Banfai; Erzsebet Kovesdi; Anita Maasz; Bela Melegh
Journal:  Pathol Oncol Res       Date:  2017-01-19       Impact factor: 3.201

2.  ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Gualtiero Ricciardi; Simona Giampaoli; Aldo Pietro Maggioni; Maurizio Averna; Maria Stella Graziani; Ferruccio Ceriotti; Alessandro Mugelli; Francesco Rossi; Gerardo Medea; Damiano Parretti; Maurizio Giuseppe Abrignani; Marcello Arca; Pasquale Perrone Filardi; Francesco Perticone; Alberico Catapano; Raffaele Griffo; Federico Nardi; Carmine Riccio; Andrea Di Lenarda; Marino Scherillo; Nicoletta Musacchio; Antonio Vittorio Panno; Giovanni Battista Zito; Mauro Campanini; Leonardo Bolognese; Pompilio Massimo Faggiano; Giuseppe Musumeci; Enrico Pusineri; Marcello Ciaccio; Enzo Bonora; Giorgio Cantelli Forti; Maria Pia Ruggieri; Claudio Cricelli; Francesco Romeo; Roberto Ferrari; Attilio Maseri
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

3.  Lipids-risk categories in omani type 2 diabetics: impact of the national cholesterol educational program.

Authors:  Ali I Al-Bahrani; Riad Bayoumi; Said A Al-Yahyaee
Journal:  Sultan Qaboos Univ Med J       Date:  2006-12

4.  Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor.

Authors:  Maxime Nowak; Audrey Helleboid-Chapman; Heidelinde Jakel; Geneviève Martin; Daniel Duran-Sandoval; Bart Staels; Edward M Rubin; Len A Pennacchio; Marja-Riitta Taskinen; Jamila Fruchart-Najib; Jean-Charles Fruchart
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

5.  The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis.

Authors:  M Hassan Murad; Ahmad Hazem; Fernando Coto-Yglesias; Svitlana Dzyubak; Shabnum Gupta; Irina Bancos; Melanie A Lane; Patricia J Erwin; Lars Berglund; Tarig Elraiyah; Victor M Montori
Journal:  BMC Endocr Disord       Date:  2012-03-31       Impact factor: 2.763

Review 6.  Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.

Authors:  Peter Alagona
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

7.  Niacin or ezetimibe for patients with, or at risk of coronary heart disease.

Authors:  Robert Guthrie
Journal:  Clin Med Insights Cardiol       Date:  2010-10-31

Review 8.  Triglycerides and risk for coronary artery disease.

Authors:  Patrick McBride
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

9.  Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats.

Authors:  Noriyasu Kanie; Takayuki Matsumoto; Tsuneo Kobayashi; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

10.  Membrane omega-3 Fatty Acid deficiency as a preventable risk factor for comorbid coronary heart disease in major depressive disorder.

Authors:  Robert K McNamara
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.